转录组分析揭示Lnc-GOLGA6A-1作为脑膜瘤复发的新型预后生物标志物
研究对64例脑膜瘤患者(16例复发、30例无复发随访>5年、18例随访<5年无复发)的福尔马林固定石蜡包埋肿瘤样本行转录组测序,并在90例独立队列中用逆转录定量PCR验证11个差异表达RNA的预后价值。Lnc-GOLGA6A-1、ISLR2和AMH对脑膜瘤复发有高预测能力,其中Lnc-GOLGA6A-1对复发风险评估最具显著性(1/风险比=1.31;P=.002)。
要点
- Lnc-GOLGA6A-1、ISLR2和AMH对预测脑膜瘤复发具有高预后能力。
- Lnc-GOLGA6A-1是复发风险评估中最显著的因子(1/风险比=1.31;P=.002)。
- 复发与非复发脑膜瘤间有69个mRNA和108个lncRNA显著差异表达。
核心结论
- 转录组测序揭示了脑膜瘤不同临床亚型的特定基因表达特征,Lnc-GOLGA6A-1转录本的表达是脑膜瘤复发最可靠的预测因子。
研究设计与样本
- 对64例具有不同临床特征的脑膜瘤患者(16例复发、30例无复发且随访>5年、18例随访<5年无复发)的福尔马林固定石蜡包埋肿瘤样本行转录组测序,使用HiSeq 2500平台(Illumina)。
- 在90例独立队列中使用逆转录定量(实时)聚合酶链反应验证11个差异表达RNA的预后价值。
主要发现
- 复发与非复发脑膜瘤间共有69个mRNA和108个lncRNA显著差异表达。
- 按性别比较观察到12个mRNA和59个lncRNA差异表达,按世界卫生组织分级比较观察到58个mRNA和98个lncRNA差异表达,按肿瘤组织发生比较观察到79个mRNA和76个lncRNA差异表达。
- Lnc-GOLGA6A-1、ISLR2和AMH对预测脑膜瘤复发显示高预后能力,Lnc-GOLGA6A-1是复发风险评估中最显著的因子(1/风险比=1.31;P=.002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningioma is the most common primary central nervous system neoplasm, accounting for about a third of all brain tumors. Because their growth rates and prognosis cannot be accurately estimated, biomarkers that enable prediction of their biological behavior would be clinically beneficial. OBJECTIVE: To identify coding and noncoding RNAs crucial in meningioma prognostication and pathogenesis. METHODS: Total RNA was purified from formalin-fixed and paraffin-embedded tumor samples of 64 patients with meningioma with distinct clinical characteristics (16 recurrent, 30 nonrecurrent with follow-up of >5 years, and 18 with follow-up of <5 years without recurrence). Transcriptomic sequencing was performed using the HiSeq 2500 platform (Illumina), and biological and functional differences between meningiomas of different types were evaluated by analyzing differentially expression of messenger RNA (mRNA) and long noncoding RNA (IncRNA). The prognostic value of 11 differentially expressed RNAs was then validated in an independent cohort of 90 patients using reverse transcription quantitative (real-time) polymerase chain reaction. RESULTS: In total, 69 mRNAs and 108 lncRNAs exhibited significant differential expression between recurrent and nonrecurrent meningiomas. Differential expression was also observed with respect to sex (12 mRNAs and 59 lncRNAs), World Health Organization grade (58 mRNAs and 98 lncRNAs), and tumor histogenesis (79 mRNAs and 76 lncRNAs). Lnc-GOLGA6A-1, ISLR2, and AMH showed high prognostic power for predicting meningioma recurrence, while lnc-GOLGA6A-1 was the most significant factor for recurrence risk estimation (1/hazard ratio = 1.31; P = .002). CONCLUSION: Transcriptomic sequencing revealed specific gene expression signatures of various clinical subtypes of meningioma. Expression of the lnc-GOLGA61-1 transcript was found to be the most reliable predictor of meningioma recurrence.
引用
- Slavik H, Balik V, Kokas FZ, et al. Transcriptomic Profiling Revealed Lnc-GOLGA6A-1 as a Novel Prognostic Biomarker of Meningioma Recurrence. Neurosurgery. 2022. PMID: 35551164. doi:10.1227/neu.0000000000002026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。